RAPHAEL PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 USD | +120.00% |
|
+0.61% | +65.00% |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 18.5 |
| Enterprise Value (EV) 1 | 18.27 |
| P/E ratio | -13 x |
| Yield | - |
| Capitalization / Revenue | - |
| EV / Revenue | - |
| EV / EBITDA | - |
| EV / FCF | -22,448,302 x |
| FCF Yield | -0% |
| Price to Book | 69.3 x |
| Nbr of stocks (in thousands) | 18,503 |
| Reference price 2 | 1.000 |
| Announcement Date | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -0.622 | -0.706 | -1.629 | -3.317 | -1.272 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.65 | -0.718 | -1.625 | -3.358 | -1.284 |
| Net income 1 | -0.65 | -0.718 | -1.625 | -3.358 | -1.284 |
| Net margin | - | - | - | - | - |
| EPS 2 | -6.500 | -7.180 | -0.1455 | -0.2341 | -0.0768 |
| Free Cash Flow | - | - | -0.7741 | 0.3739 | -0.814 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/2/21 | 7/2/21 | 3/30/22 | 3/24/23 | 3/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 0.26 | - | - | - |
| Net Cash position 1 | 0.05 | - | 0.15 | 0.29 | 0.23 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | -0.77 | 0.37 | -0.81 |
| ROE (net income / shareholders' equity) | - | -870% | -3,824% | -2,870% | -688% |
| ROA (Net income/ Total Assets) | - | -166% | -273% | -549% | -237% |
| Assets 1 | - | 0.432 | 0.5945 | 0.6115 | 0.5427 |
| Book Value Per Share 2 | 2.080 | -0.4300 | 0.0100 | 0.0100 | 0.0100 |
| Cash Flow per Share 2 | 0.5000 | 0.9500 | 0.0100 | 0.0200 | 0.0100 |
| Capex | - | - | - | 0 | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/2/21 | 7/2/21 | 3/30/22 | 3/24/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +65.00% | 30.86M | |
| +38.36% | 52.73B | |
| +36.73% | 39B | |
| -8.63% | 38.52B | |
| +25.46% | 30.38B | |
| -11.17% | 26.39B | |
| +11.44% | 26.08B | |
| +45.09% | 14.15B | |
| +32.93% | 12.6B | |
| -5.30% | 11.51B |
- Stock Market
- Equities
- RAPH Stock
- Financials Raphael Pharmaceutical Inc.
